Celularity and MuseCell Innovations are establishing U.S. manufacturing of Dezawa MuseCells—a stem cell-derived therapeutic—at Celularity's New Jersey facility. This partnership scales production of cellular products that may support tissue regeneration and cellular function across multiple therapeutic areas.
Key Points
- U.S. manufacturing of Dezawa MuseCells launches at Celularity's New Jersey cGMP facility
- Production includes MuseExosomes and MuseSecretome derived products from licensed Dezawa Method
- Partnership projects $300M in purchases over five years, 200+ jobs created
Longevity Analysis
Domestication of allogeneic stem cell manufacturing represents a maturation of cellular medicine beyond academic development. MuseCells—derived from perinatal, bone marrow, and adipose tissues—function as signaling agents that modulate inflammatory and regenerative pathways, with exosome and secretome fractions offering cell-free alternatives that may preserve bioactivity while reducing immunogenicity. Scaling manufacturing under validated cGMP processes is essential for translating cell-based interventions into clinical evidence; the breadth of source materials and product formats suggests the therapeutic window extends across multiple tissues and functional domains, from structural support to metabolic signaling.
Original published by LT Wire.